{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:52:33Z","timestamp":1788915153423,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Vanboeijen, Intellectual Disability Centre, Assen, The Netherlands"},{"name":"De Open Ankh, Foundation Services Health Care, Soesterberg, the Netherlands"},{"DOI":"10.13039\/501100007344","name":"Achmea Assurance Health Care, the Netherlands","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007344","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Supporting Foundation's Heeren Loo, Intellectual Disability Centre Amersfoort, the Netherlands"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Developmental Disabilities"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ridd.2013.05.016","type":"journal-article","created":{"date-parts":[[2013,6,20]],"date-time":"2013-06-20T05:33:12Z","timestamp":1371706392000},"page":"2799-2809","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Determinants of physical health parameters in individuals with intellectual disability who use long-term antipsychotics"],"prefix":"10.1016","volume":"34","author":[{"given":"Gerda","family":"de Kuijper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen","family":"Evenhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans","family":"Scholte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter J.","family":"Hoekstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ridd.2013.05.016_bib0005","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1176\/appi.ajp.160.9.1618","article-title":"Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: A prospective study","volume":"160","author":"Abraham","year":"2003","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2013.05.016_bib0010","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1515\/JPEM.2011.019","article-title":"The effects of antiepileptic drugs on the relationships between leptin levels and bone turnover in prepubertal children with epilepsy","volume":"24","author":"Aksoy","year":"2011","journal-title":"Journal of Pediatric Endocrinology & Metabolism"},{"key":"10.1016\/j.ridd.2013.05.016_bib0015","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.pnpbp.2009.01.010","article-title":"Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in russian psychiatric inpatients from siberia","volume":"33","author":"Al Hadithy","year":"2009","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"issue":"Suppl. 9","key":"10.1016\/j.ridd.2013.05.016_bib0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1528-1167.2007.01402.x","article-title":"Weight issues for people with epilepsy \u2013 A review","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.ridd.2013.05.016_bib0025","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2165\/11530020-000000000-00000","article-title":"Adverse endocrine and metabolic effects of psychotropic drugs: Selective clinical review","volume":"23","author":"Bhuvaneswar","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ridd.2013.05.016_bib0030","first-page":"413","article-title":"Akathisia in adults with mental retardation: Development of the akathisia ratings of movement scale (ARMS)","volume":"101","author":"Bodfish","year":"1997","journal-title":"American Journal of Mental Retardation"},{"key":"10.1016\/j.ridd.2013.05.016_bib0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/JCP.0b013e3182075587","article-title":"Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women","volume":"31","author":"Bolton","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.ridd.2013.05.016_bib0040","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.berh.2005.06.004","article-title":"What is the role of DXA, QUS and bone markers in fracture prediction, treatment allocation and monitoring?","volume":"19","author":"Briot","year":"2005","journal-title":"Best Practice & Research Clinical Rheumatology"},{"key":"10.1016\/j.ridd.2013.05.016_bib0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/0269881107088435","article-title":"A review of the association between antipsychotic use and hyperprolactinaemia","volume":"22","author":"Bushe","year":"2008","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.ridd.2013.05.016_bib0050","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0269881107088436","article-title":"Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics","volume":"22","author":"Bushe","year":"2008","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.ridd.2013.05.016_bib0055","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/FPC.0b013e328329a60f","article-title":"Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents","volume":"19","author":"Calarge","year":"2009","journal-title":"Pharmacogenetics and Genomics"},{"key":"10.1016\/j.ridd.2013.05.016_bib0060","article-title":"Effects of controlled discontinuation of long-term used antipsychotics for behavioural symptoms in individuals with intellectual disability","author":"de Kuijper","year":"2012","journal-title":"Journal of Intellectual Disability Research"},{"key":"10.1016\/j.ridd.2013.05.016_bib0065","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2788.2010.01275.x","article-title":"Use of antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: Prevalence and reasons for prescription","volume":"54","author":"de Kuijper","year":"2010","journal-title":"Journal of Intellectual Disability Research"},{"key":"10.1016\/j.ridd.2013.05.016_bib0070","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ridd.2011.09.022","article-title":"Overweight and obesity in older people with intellectual disability","volume":"33","author":"de Winter","year":"2012","journal-title":"Research in Developmental Disabilities"},{"key":"10.1016\/j.ridd.2013.05.016_bib0075","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1352\/1944-7558-114.6.427","article-title":"Prevalence of cardiovascular risk factors in older people with intellectual disability","volume":"114","author":"de Winter","year":"2009","journal-title":"American Journal on Intellectual and Developmental Disabilities"},{"key":"10.1016\/j.ridd.2013.05.016_bib0080","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/fampra\/cmq079","article-title":"Metabolic syndrome in 25% of older people with intellectual disability","volume":"28","author":"de Winter","year":"2011","journal-title":"Family Practice"},{"key":"10.1016\/j.ridd.2013.05.016_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnpbp.2009.11.009","article-title":"The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain?","volume":"34","author":"Deng","year":"2010","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1016\/j.ridd.2013.05.016_bib0090","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-0447.1994.tb01579.x","article-title":"Dyskinesia in mentally handicapped women: Relationship to level of handicap, age and neuroleptic exposure","volume":"90","author":"Farren","year":"1994","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1016\/j.ridd.2013.05.016_bib0095","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/PL00004183","article-title":"Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy","volume":"11","author":"Fink","year":"2000","journal-title":"Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA"},{"key":"10.1016\/j.ridd.2013.05.016_bib0100","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ridd.2010.01.017","article-title":"Tardive dyskinesia and intellectual disability: An examination of demographics and topography in adults with dual diagnosis and atypical antipsychotic use","volume":"31","author":"Fodstad","year":"2010","journal-title":"Research in Developmental Disabilities"},{"key":"10.1016\/j.ridd.2013.05.016_bib0105","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1590\/S0004-282X2010000200024","article-title":"Modification in body weight associated with antiepileptic drugs","volume":"68","author":"Gaspari","year":"2010","journal-title":"Arquivos de Neuro-Psiquiatria"},{"key":"10.1016\/j.ridd.2013.05.016_bib0110","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2788.2011.01468.x","article-title":"The overweight: Obesity and plasma lipids in adults with intellectual disability and mental illness","volume":"56","author":"Gazizova","year":"2011","journal-title":"Journal of Intellectual Disability Research"},{"key":"10.1016\/j.ridd.2013.05.016_bib0115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00228-006-0234-8","article-title":"Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: Associations with dopamine and serotonin receptor and transporter polymorphisms","volume":"63","author":"Guzey","year":"2007","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.ridd.2013.05.016_bib0120","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2165\/00023210-200721080-00003","article-title":"Osteoporosis schizophrenia and antipsychotics: The need for a comprehensive multifactorial evaluation","volume":"21","author":"Halbreich","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ridd.2013.05.016_bib0125","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2265.2010.03814.x","article-title":"Antipsychotics and hyperprolactinaemia: Mechanisms consequences and management","volume":"74","author":"Holt","year":"2011","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.ridd.2013.05.016_bib0130","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ridd.2011.09.005","article-title":"The risk of metabolic syndrome among institutionalized adults with intellectual disabilities","volume":"33","author":"Hsu","year":"2012","journal-title":"Research in Developmental Disabilities"},{"key":"10.1016\/j.ridd.2013.05.016_bib0135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3371\/CSRP.4.3.2","article-title":"Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications","volume":"4","author":"Jerrell","year":"2010","journal-title":"Clinical Schizophrenia & Related Psychoses"},{"key":"10.1016\/j.ridd.2013.05.016_bib0140","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archpsyc.1982.04290040069010","article-title":"Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979","volume":"39","author":"Kane","year":"1982","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.ridd.2013.05.016_bib0145","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.clinbiochem.2012.03.023","article-title":"Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum","volume":"45","author":"Koivula","year":"2012","journal-title":"Clinical Biochemistry"},{"key":"10.1016\/j.ridd.2013.05.016_bib0150","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00228-006-0174-3","article-title":"An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice","volume":"62","author":"Leeming","year":"2006","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.ridd.2013.05.016_bib0155","doi-asserted-by":"crossref","first-page":"405","DOI":"10.31887\/DCNS.2009.11.4\/tlencz","article-title":"Pharmacogenetics of antipsychotic-induced side effects","volume":"11","author":"Lencz","year":"2009","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"10.1016\/j.ridd.2013.05.016_bib0160","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.ridd.2012.03.027","article-title":"High blood pressure in adults with disabilities: Influence of gender body weight and health behaviors","volume":"33","author":"Lin","year":"2012","journal-title":"Research in Developmental Disabilities"},{"key":"10.1016\/j.ridd.2013.05.016_bib0165","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.schres.2006.04.008","article-title":"The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia","volume":"86","author":"Liou","year":"2006","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.ridd.2013.05.016_bib0170","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/JCP.0b013e31822cfff2","article-title":"DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers","volume":"31","author":"Lopez-Rodriguez","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.ridd.2013.05.016_bib0175","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/oxfordjournals.aje.a116813","article-title":"Simulation study of confounder-selection strategies","volume":"138","author":"Maldonado","year":"1993","journal-title":"American Journal of Epidemiology"},{"key":"10.1016\/j.ridd.2013.05.016_bib0180","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ridd.2009.08.002","article-title":"Risk factors for tardive dyskinesia in adults with intellectual disability, comorbid psychopathology and long-term psychotropic use","volume":"31","author":"Matson","year":"2010","journal-title":"Research in Developmental Disabilities"},{"key":"10.1016\/j.ridd.2013.05.016_bib0185","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.ridd.2010.05.005","article-title":"Antipsychotic drug side effects for persons with intellectual disability","volume":"31","author":"Matson","year":"2010","journal-title":"Research in Developmental Disabilities"},{"key":"10.1016\/j.ridd.2013.05.016_bib0190","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2788.2006.00915.x","article-title":"Lifestyle and health behaviours of adults with an intellectual disability","volume":"51","author":"McGuire","year":"2007","journal-title":"Journal of Intellectual Disability Research"},{"key":"10.1016\/j.ridd.2013.05.016_bib0195","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.4088\/JCP.v66n0912","article-title":"Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled","volume":"66","author":"McKee","year":"2005","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2013.05.016_bib0200","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.4088\/JCP.v65n1205","article-title":"Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism","volume":"65","author":"Misra","year":"2004","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2013.05.016_bib0205","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/sj.tpj.6500422","article-title":"The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: A cross-sectional study","volume":"7","author":"Mulder","year":"2007","journal-title":"The Pharmacogenomics Journal"},{"key":"10.1016\/j.ridd.2013.05.016_bib0210","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/JCP.0b013e3180a76dc0","article-title":"The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia","volume":"27","author":"Mulder","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"Suppl 1","key":"10.1016\/j.ridd.2013.05.016_bib0215","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medications: A review of recent evidence","volume":"68","author":"Newcomer","year":"2007","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.ridd.2013.05.016_bib0220","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment \u2013 Pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.ridd.2013.05.016_bib0225","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.pnpbp.2005.03.019","article-title":"The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment","volume":"29","author":"Reynolds","year":"2005","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1016\/j.ridd.2013.05.016_bib0230","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/01.jcp.0000096247.29231.3a","article-title":"Chlorpromazine equivalents versus defined daily doses: How to compare antipsychotic drug doses?","volume":"23","author":"Rijcken","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.ridd.2013.05.016_bib0235","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2217\/pgs.11.67","article-title":"Pharmacogenetic testing to predict antipsychotic-induced weight gain: A systematic review","volume":"12","author":"Risselada","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ridd.2013.05.016_bib0240","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/YPG.0b013e32832080ad","article-title":"Association of the dopamine D3 receptor Ser9Gly and of the serotonin 2C receptor gene polymorphisms with tardive dyskinesia in Greeks with chronic schizophrenic disorder","volume":"19","author":"Rizos","year":"2009","journal-title":"Psychiatric Genetics"},{"key":"10.1016\/j.ridd.2013.05.016_bib0245","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.pnpbp.2006.12.021","article-title":"-759C\/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment","volume":"31","author":"Ryu","year":"2007","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1016\/j.ridd.2013.05.016_bib0250","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/000486749202600208","article-title":"Drug-induced movement disorders in institutionalised adults with mental retardation: Clinical characteristics and risk factors","volume":"26","author":"Sachdev","year":"1992","journal-title":"The Australian and New Zealand Journal of Psychiatry"},{"key":"10.1016\/j.ridd.2013.05.016_bib0255","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2788.2010.01346.x","article-title":"Osteoporosis in people with intellectual disabilities: A review and a brief study of risk factors for osteoporosis in a community sample of people with intellectual disabilities","volume":"55","author":"Srikanth","year":"2011","journal-title":"Journal of Intellectual Disability Research"},{"key":"10.1016\/j.ridd.2013.05.016_bib0260","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1352\/1944-7558-116.6.401","article-title":"Overweight and obesity among adults with intellectual disabilities who use intellectual disability\/developmental disability services in 20 U.S. states","volume":"116","author":"Stancliffe","year":"2011","journal-title":"American Journal on Intellectual and Developmental Disabilities"},{"key":"10.1016\/j.ridd.2013.05.016_bib0265","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3109\/13668251003717928","article-title":"Obesity and intellectual disability in New Zealand","volume":"35","author":"Stedman","year":"2010","journal-title":"Journal of Intellectual & Developmental Disability"},{"key":"10.1016\/j.ridd.2013.05.016_bib0270","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-2002-19838","article-title":"Psychotropic drug use in intellectually disabled group-home residents with behavioural problems","volume":"35","author":"Stolker","year":"2002","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.ridd.2013.05.016_bib0275","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0091-3057(89)90271-2","article-title":"Lifetime antipsychotic-drug exposure, dyskinesia and related movement disorders in the developmentally disabled","volume":"34","author":"Stone","year":"1989","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.ridd.2013.05.016_bib0280","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00228-005-0935-4","article-title":"Drug utilisation by children and adolescents with mental retardation: A population study","volume":"61","author":"Tobi","year":"2005","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.ridd.2013.05.016_bib0285","first-page":"1083","article-title":"Drug use by mentally handicapped persons in institutions and family-replacing residential facilities","volume":"139","author":"van Schrojenstein Lantman-de Valk","year":"1995","journal-title":"Nederlands Tijdschrift Voor Geneeskunde"},{"key":"10.1016\/j.ridd.2013.05.016_bib0290","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1046\/j.1365-2788.1998.00152.x","article-title":"Osteoporosis and intellectual disability: Is there any relation?","volume":"42","author":"Wagemans","year":"1998","journal-title":"Journal of Intellectual Disability Research"},{"key":"10.1016\/j.ridd.2013.05.016_bib0295","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/cap.2009.0050","article-title":"A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit\/hyperactivity disorder clinic","volume":"19","author":"Weiss","year":"2009","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1016\/j.ridd.2013.05.016_bib0300","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1046\/j.1440-1819.2002.01038.x","article-title":"Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in korean schizophrenics","volume":"56","author":"Woo","year":"2002","journal-title":"Psychiatry and Clinical Neurosciences"},{"key":"10.1016\/j.ridd.2013.05.016_bib0305","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1037\/1064-1297.9.3.285","article-title":"Risk factors for tardive dyskinesia in a large population of youths and adults","volume":"9","author":"Wszola","year":"2001","journal-title":"Experimental and Clinical Psychopharmacology"},{"key":"10.1016\/j.ridd.2013.05.016_bib0310","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4306\/pi.2011.8.3.256","article-title":"Effects of long-term combination treatment with valproate and atypical antipsychotics on bone mineral density and bone metabolism in premenopausal patients with bipolar disorder: A preliminary study","volume":"8","author":"Yang","year":"2011","journal-title":"Psychiatry Investigation"}],"container-title":["Research in Developmental Disabilities"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089142221300200X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089142221300200X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:49:32Z","timestamp":1760194172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089142221300200X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":62,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S089142221300200X"],"URL":"https:\/\/doi.org\/10.1016\/j.ridd.2013.05.016","relation":{},"ISSN":["0891-4222"],"issn-type":[{"value":"0891-4222","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determinants of physical health parameters in individuals with intellectual disability who use long-term antipsychotics","name":"articletitle","label":"Article Title"},{"value":"Research in Developmental Disabilities","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ridd.2013.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}